The statistic, in four numbers
The figure
$27.5B
Part D GLP-1 spending, 2024, before rebates
Records
11
rows in the table and the files
Source updated
Jun 2026
CMS data updated
Read by us
Oct 2026
from Centers for Medicare & Medicaid Services
The numbers, to scale
Sum of every GLP-1 brand's total spending. Source: CMS Medicare Part D Spending by Drug, updated June 25, 2026.
Each brand's total Part D spending, all manufacturers combined.
Every GLP-1 brand in Part D (11), highest 2024 spending first
| Brand | Generic | 2020 | 2024 spending | Claims | Beneficiaries | Per beneficiary |
|---|---|---|---|---|---|---|
| Ozempic | Semaglutide | $1,455,812,267 | $12,970,296,347 | 10,417,182 | 1,952,637 | $6,642 |
| Mounjaro | Tirzepatide | None reported | $6,336,942,641 | 5,105,397 | 894,581 | $7,084 |
| Trulicity | Dulaglutide | $3,284,873,062 | $5,454,134,725 | 4,305,141 | 788,716 | $6,915 |
| Rybelsus | Semaglutide | $73,444,409 | $1,890,082,026 | 1,251,733 | 309,993 | $6,097 |
| Wegovy | Semaglutide | None reported | $301,283,291 | 211,575 | 52,961 | $5,689 |
| Bydureon Bcise | Exenatide Microspheres | $266,160,951 | $215,354,678 | 178,931 | 38,059 | $5,658 |
| Victoza 3-Pak | Liraglutide | $1,545,815,415 | $203,063,050 | 181,068 | 62,754 | $3,236 |
| Victoza 2-Pak | Liraglutide | $349,476,159 | $77,832,721 | 108,521 | 41,126 | $1,893 |
| Liraglutide | Liraglutide | None reported | $48,095,824 | 62,254 | 24,405 | $1,971 |
| Byetta | Exenatide | $47,676,632 | $15,877,480 | 11,712 | 3,043 | $5,218 |
| Zepbound | Tirzepatide | None reported | $387,343 | 353 | 245 | $1,581 |
"None reported" marks years a brand had no Part D spending reported (it was not yet approved or not covered). The export carries every year. All 11 rows, with every column, are in the CSV and JSON.
How the number is computed
Sum of "Total Spending" for each year across every GLP-1 brand's "Overall" row (all manufacturers combined) in CMS's Medicare Part D Spending by Drug dataset, data year 2024.
Included
- Brands: Ozempic, Mounjaro, Trulicity, Rybelsus, Wegovy, Bydureon Bcise, Victoza 3-Pak, Victoza 2-Pak, Liraglutide, Byetta, Zepbound.
Excluded
- Insulin combinations: Soliqua (insulin glargine and lixisenatide); Xultophy (insulin degludec and liraglutide).
- Beneficiaries are not summed across brands: one person can fill two brands in a year.
What this does not show
- Spending is gross drug cost (what plans and patients paid pharmacies), before manufacturer rebates and discounts.
- Medicare Part D does not cover drugs prescribed for weight loss alone; most of this spending is for type 2 diabetes, with Wegovy and Zepbound covered for other approved uses.
- CMS flags a brand-year as an outlier when its average spending per unit looks unusual: Wegovy 2023.
Recent changes to this page
- Source re-read by us; the figure reads $27.5B Part D GLP-1 spending, 2024, before rebates
- Page published
A figure wrong? Tell us at hello@pricetrackerglp1.com. Every correction is dated on /corrections.
Receipts
2 sources · read October 4, 2026
- 01read
Five calendar years per brand: total spending, claims, dosage units, beneficiaries.
CMS, Medicare Part D Spending by Drug, data year 2024 (data.cms.gov), updated June 25, 2026 - 02read
How to cite this page
Free to reuse under CC BY 4.0: quote the number, credit PriceTracker GLP-1 with a link, and name the federal source. The underlying records are public; our counts, matching and files are the work you are crediting.
PriceTracker GLP-1. (2026, October 4). Medicare Part D spending on GLP-1 drugs, 2020 to 2024 [Data set]. Based on Centers for Medicare & Medicaid Services data, cms data updated June 25, 2026. https://pricetrackerglp1.com/data/medicare-part-d-glp1-spending
<p>Medicare Part D spent $27.5 billion on GLP-1 drugs in 2024, up from $7.0 billion in 2020, according to CMS Medicare Part D Spending by Drug data updated June 25, 2026. Source: <a href="https://pricetrackerglp1.com/data/medicare-part-d-glp1-spending">PriceTracker GLP-1</a> (CC BY 4.0).</p>
https://pricetrackerglp1.com/data/medicare-part-d-glp1-spending.csv https://pricetrackerglp1.com/data/medicare-part-d-glp1-spending.json
This statistic: common questions
What does this statistic count?
Medicare Part D spent $27.5 billion on GLP-1 drugs in 2024, up from $7.0 billion in 2020, according to CMS Medicare Part D Spending by Drug data updated June 25, 2026.
How is the number computed?
Sum of "Total Spending" for each year across every GLP-1 brand's "Overall" row (all manufacturers combined) in CMS's Medicare Part D Spending by Drug dataset, data year 2024.
Where does the data come from?
Centers for Medicare & Medicaid Services: CMS, Medicare Part D Spending by Drug, data year 2024 (data.cms.gov), updated June 25, 2026; CMS, the same dataset as CSV. CMS data updated June 25, 2026; we last read it on October 4, 2026.
Can I reuse this data?
Yes, under CC BY 4.0: credit "PriceTracker GLP-1, pricetrackerglp1.com" with a link and name the federal source. Every row is in the CSV (https://pricetrackerglp1.com/data/medicare-part-d-glp1-spending.csv) and the JSON (https://pricetrackerglp1.com/data/medicare-part-d-glp1-spending.json).